Midostaurin | List of Frontiers open access articles

Original Research

Published on 18 Jun 2019

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study

in Cancer Molecular Targets and Therapeutics

Ning Ji
Yuqi Yang
Chao-Yun Cai
Jing-Quan Wang
Zi-Ning Lei
Zhuo-Xun Wu
Qingbin Cui
Dong-Hua Yang
Zhe-Sheng Chen
Dexin Kong

Frontiers in Oncology

doi 10.3389/fonc.2019.00514

7,203 views
28 citations

Case Report

Published on 10 Aug 2023

Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level

in Cancer Immunity and Immunotherapy

Meng-Ke Liu
Feng Liu
Yu-Ting Dai
Xiang-Qin Weng
Li-Li Cheng
Li-Quan Fan
Han Liu
Lu Jiang
Xiao-Jian Sun
Hai Fang

Frontiers in Immunology

doi 10.3389/fimmu.2023.1210909

5,193 views
3 citations

Original Research

Published on 29 Jul 2024

ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics

in Medicinal and Pharmaceutical Chemistry

Mohammed Alrouji
Sabina Yasmin
Fahad A Alhumaydhi
Sharaf E. Sharaf
Moyad Shahwan
Anas Shamsi

Frontiers in Chemistry

doi 10.3389/fchem.2024.1392650

2,864 views

Perspective

Published on 08 Feb 2022

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

in Cancer Molecular Targets and Therapeutics

Zheng Li
Jun Wang
Shuai-Shuai Ge
Qiao-Cheng Qiu
Jia-Hui Du
Shuang-Shuang Shan
Xiang-Dong Shen
Chao-Ling Wan
Bin-Ru Wang
De-Pei Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.841276

8,009 views
16 citations

Methods

Published on 18 Oct 2022

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases

in Biological Modeling and Simulation

Yongkai Hong
Dantian Chen
Yaqing Jin
Mian Zu
Yin Zhang

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2022.971768

3,799 views
1 citation

Mini Review

Published on 14 Apr 2020

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

in Pharmacology of Anti-Cancer Drugs

Miguel Piris-Villaespesa
Ivan Alvarez-Twose

Frontiers in Pharmacology

doi 10.3389/fphar.2020.00443

18,351 views
29 citations

Case Report

Published on 30 Sep 2021

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia

in Hematologic Malignancies

Samantha Bruno
Lorenza Bandini
Agnese Patuelli
Valentina Robustelli
Claudia Venturi
Manuela Mancini
Dorian Forte
Sara De Santis
Cecilia Monaldi
Alessandra Grassi

Frontiers in Oncology

doi 10.3389/fonc.2021.728613

5,054 views
6 citations

Original Research

Published on 10 May 2024

In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study

in Translational Pharmacology

Raluca-Andrada Munteanu
Adrian Bogdan Tigu
Richard Feder
Andra-Sorina Tatar
Diana Gulei
Ciprian Tomuleasa
Sanda Boca

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1382399

4,652 views
3 citations

Original Research

Published on 15 Aug 2025

Identification of biomarkers based on ubiquitin-correlated genes for predicting immune profile and drug sensitivity in lung adenocarcinoma

in Pharmacology of Anti-Cancer Drugs

Yue Li
Wei Tian
Chen Chen
Hailin Liu
Zhenfa Zhang
Changli Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1646396

2,231 views
1 citation

Original Research

Published on 19 Sep 2024

Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis

in Hematologic Malignancies

Giuseppe Sapienza
Marta Castronovo
Stefania Tringali
Roberto Bono
Cristina Rotolo
Antonino Mulè
Valeria Calafiore
Caterina Patti
Cecilia Agueli
Valentina Randazzo

Frontiers in Oncology

doi 10.3389/fonc.2024.1441254

2,858 views
4 citations

Original Research

Published on 01 Dec 2022

Integrated genomic analysis to identify druggable targets for pancreatic cancer

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Eko Mugiyanto
Wirawan Adikusuma
Lalu Muhammad Irham
Wan-Chen Huang
Wei-Chiao Chang
Chun-Nan Kuo

Frontiers in Oncology

doi 10.3389/fonc.2022.989077

5,140 views
8 citations

Original Research

Published on 19 Dec 2022

Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis

in Pharmacology of Anti-Cancer Drugs

Mengfeng Liu
Qifan Xiao
Xiran Yu
Yujie Zhao
Changfa Qu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1081244

4,473 views
5 citations

Original Research

Published on 25 Aug 2022

In-silico probing of AML related RUNX1 cancer-associated missense mutations: Predicted relationships to DNA binding and drug interactions

in Molecular Diagnostics and Therapeutics

Hanif Ullah
Baoyun Zhang
Narendra Kumar Sharma
Pierre D. McCrea
Yogesh Srivastava

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2022.981020

5,249 views
2 citations

Original Research

Published on 12 Mar 2026

Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical and in vitro validation in prostate cancer

in Cancer Immunity and Immunotherapy

Yuanan Li
Bingnan Lu
Zihui Zhao
Ming Gong
Donghao Lyu
Haoyu Zhang
Runzhi Huang
Yuntao Yao
Yifan Liu
Ping Huang

Frontiers in Immunology

doi 10.3389/fimmu.2026.1616889

709 views

Systematic Review

Accepted on 23 Apr 2026

Efficacy and Safety of FLT3 Inhibitors for Acute Myeloid Leukemia: A Network Meta-Analysis

in Hematologic Malignancies

瑶瑶许
铭嘉李
Gao Yao
Gan Huang
坚英曾

Frontiers in Oncology

230 views

Articles

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study

Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level

ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia

In vivo imaging system (IVIS) therapeutic assessment of tyrosine kinase inhibitor-loaded gold nanocarriers for acute myeloid leukemia: a pilot study

Identification of biomarkers based on ubiquitin-correlated genes for predicting immune profile and drug sensitivity in lung adenocarcinoma

Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis

Integrated genomic analysis to identify druggable targets for pancreatic cancer

Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis

In-silico probing of AML related RUNX1 cancer-associated missense mutations: Predicted relationships to DNA binding and drug interactions

Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical and in vitro validation in prostate cancer

Efficacy and Safety of FLT3 Inhibitors for Acute Myeloid Leukemia: A Network Meta-Analysis